| 1 |
33063648 | Molecular dynamic mechanism(s) of inhibition of bioactive antiviral phytochemical compounds targeting cytochrome P450 3A4 and P-glycoprotein. | 2022 Feb |
1 |
| 2 |
33974624 | Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients. | 2021 |
1 |
| 3 |
32641296 | Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. | 2020 Aug 20 |
2 |
| 4 |
30470150 | Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug. | 2019 Jun - Jul |
1 |
| 5 |
28038962 | Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. | 2017 Feb |
1 |
| 6 |
28569994 | Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir. | 2017 Oct |
4 |
| 7 |
30227099 | An Innovative, Collaborative, and Strategic Approach to Proactively Evaluate and Update Drug Interactions Based on Prescribing Information of Newly Approved Medicinal Products. | 2017 Nov |
1 |
| 8 |
26741368 | Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4. | 2016 |
1 |
| 9 |
26818566 | The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients. | 2016 Jan 27 |
1 |
| 10 |
27142945 | Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans. | 2016 May |
1 |
| 11 |
25391550 | CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman. | 2015 Jan |
1 |
| 12 |
25407158 | Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. | 2015 Mar |
1 |
| 13 |
24727459 | Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir. | 2014 Apr 10 |
2 |
| 14 |
24950369 | CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. | 2014 Sep |
4 |
| 15 |
24986243 | Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs. | 2014 Jul 2 |
3 |
| 16 |
25394094 | Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients. | 2014 |
1 |
| 17 |
24110489 | Compartmental pharmacokinetic modeling of lopinavir in humans. | 2013 |
1 |
| 18 |
21953914 | CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir. | 2012 Jan |
1 |
| 19 |
22421793 | Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme. | 2012 Mar 15 |
1 |
| 20 |
20878151 | Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. | 2011 Feb |
1 |
| 21 |
21491455 | An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. | 2011 Jun |
9 |
| 22 |
21819807 | [Evidence-based therapeutic drug monitoring of lopinavir]. | 2011 May-Jun |
1 |
| 23 |
22312553 | Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults. | 2011 |
1 |
| 24 |
27393203 | [Not Available]. | 2011 May-Jun |
1 |
| 25 |
19931478 | Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. | 2010 Jan |
1 |
| 26 |
20590614 | Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. | 2010 Jul |
1 |
| 27 |
20861742 | Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. | 2010 Dec 15 |
2 |
| 28 |
18183034 | Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. | 2008 Jul |
4 |
| 29 |
18455890 | Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. | 2008 Jul 9 |
2 |
| 30 |
16639344 | Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. | 2006 May |
1 |
| 31 |
15247556 | Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. | 2004 Aug 15 |
2 |
| 32 |
12724045 | Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. | 2003 Mar |
5 |
| 33 |
12086554 | Kaletra (lopinavir/ritonavir). | 2002 Jul-Aug |
1 |
| 34 |
11596909 | Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC. | 2001 |
2 |
| 35 |
10421617 | Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. | 1999 Aug |
1 |